The first 60 days: Low-grade serous ovarian cancer
Low-grade serous cancer is the slow-growing, chemotherapy-resistant cousin of the common ovarian cancer. Surgery and hormone therapy are its mainstays, and MEK inhibitors, alone or combined with a FAK inhibitor, are the first drugs shown to shrink it reliably. Below, week by week, is what OnCo's record of Low-grade serous ovarian cancer says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- SurgeonNamed in the standard of care for: First line, Recurrent disease.
- Medical oncologistNamed in the standard of care for: First line, Recurrent disease, Maintenance.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Complete cytoreductive surgery; carboplatin-paclitaxel followed by letrozole maintenance, or letrozole alone in selected patients.
Trametinib (GOG 281) or avutometinib plus defactinib for KRAS-mutant tumours; aromatase inhibitors; secondary surgery where complete resection is possible.
Letrozole after first-line treatment, continued for years while tolerated.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example KRAS, BRAF and NRAS mutations, Oestrogen and progesterone receptor expression, Wild-type TP53, CA-125), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include KRAS-mutant, BRAF or NRAS-mutant, MAPK wild-type.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
First line
- For my situation (first line), which of the standard options do you recommend and why?Guideline options include: Complete cytoreductive surgery; carboplatin-paclitaxel followed by letrozole maintenance, or letrozole alone in selected patients.
- Am I a candidate for Carboplatin, Paclitaxel / nab-paclitaxel, Letrozole (and other aromatase inhibitors), and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Recurrent disease
- For my situation (recurrent disease), which of the standard options do you recommend and why?Guideline options include: Trametinib (GOG 281) or avutometinib plus defactinib for KRAS-mutant tumours; aromatase inhibitors; secondary surgery where complete resection is possible.
- Am I a candidate for Trametinib, Avutometinib + defactinib, Letrozole (and other aromatase inhibitors), and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Maintenance
- For my situation (maintenance), which of the standard options do you recommend and why?Guideline options include: Letrozole after first-line treatment, continued for years while tolerated.
- Am I a candidate for Letrozole (and other aromatase inhibitors), and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Avutometinib + defactinib, Trametinib?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Whether first-line chemotherapy adds anything to surgery and hormone therapy”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Options for MAPK wild-type tumours”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Low-grade serous ovarian cancer: the full pageLow-grade serous cancer is the slow-growing, chemotherapy-resistant cousin of the common ovarian cancer. Surgery and hormone therapy are its mainstays, and MEK inhibitors, alone or combined with a FAK inhibitor, are the first drugs shown to shrink it reliably.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.